blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3395339

EP3395339 - RAPID DISSOLUTION FORMULATION OF A CINACALCET HCL [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  14.10.2022
Database last updated on 18.11.2024
FormerThe patent has been granted
Status updated on  15.03.2019
FormerGrant of patent is intended
Status updated on  03.03.2019
FormerExamination is in progress
Status updated on  19.10.2018
FormerRequest for examination was made
Status updated on  28.09.2018
Most recent event   Tooltip14.10.2022Revocation of patentpublished on 16.11.2022  [2022/46]
Applicant(s)For all designated states
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 / US
[2019/49]
Former [2018/44]For all designated states
Amgen, Inc
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 / US
Inventor(s)01 / ÁLVAREZ, Francisco J.
817 Paseo De Leon
Newbury Park, CA California 91320 / US
02 / JU, Tzuchi R.
1438 N. Butler Court
Vernon Hills, IL Illinois 60061 / US
03 / LIN, Hung-Ren H.
5086 Durant Court
Oak Park, CA California 91377 / US
04 / LAWRENCE, Glen Cary
One Amgen Center Drive
Thousand Oaks, CA California 91320-1799 / US
 [2018/44]
Representative(s)Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
[N/P]
Former [2018/44]EIP
EIP Europe LLP
Fairfax House
15 Fulwood Place
London WC1V 6HU / GB
Application number, filing date18175497.910.09.2004
[2018/44]
Priority number, dateUS20030502219P12.09.2003         Original published format: US 502219 P
[2018/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3395339
Date:31.10.2018
Language:EN
[2018/44]
Type: B1 Patent specification 
No.:EP3395339
Date:17.04.2019
Language:EN
[2019/16]
Type: B8 Corrected title page of specification 
No.:EP3395339
Date:11.12.2019
[2019/50]
Search report(s)(Supplementary) European search report - dispatched on:EP01.10.2018
ClassificationIPC:A61K31/135, A61K9/28, A61K9/20, A61P5/18
[2019/11]
CPC:
A61K31/135 (EP,KR,US); A61K9/20 (KR); A61K31/00 (EP,US);
A61K31/137 (EP,US); A61K9/2077 (EP,US); A61K9/2866 (EP,US);
A61P3/00 (EP); A61P3/14 (EP); A61P43/00 (EP);
A61P5/00 (EP); A61P5/18 (EP); A61P5/20 (EP) (-)
Former IPC [2018/44]A61K31/00, A61K31/135, A61K9/28, A61K9/20, A61P5/18
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2018/44]
TitleGerman:SCHNELLAUFLÖSUNGSFORMULIERUNG ENTHALTEND CINACALCET HCL[2018/44]
English:RAPID DISSOLUTION FORMULATION OF A CINACALCET HCL[2018/44]
French:FORMULATION À DISSOLUTION RAPIDE DE CINACALCET HCL[2018/44]
Examination procedure01.06.2018Examination requested  [2018/44]
01.06.2018Date on which the examining division has become responsible
18.10.2018Despatch of a communication from the examining division (Time limit: M04)
12.12.2018Reply to a communication from the examining division
21.01.2019Despatch of a communication from the examining division (Time limit: M04)
25.01.2019Reply to a communication from the examining division
04.03.2019Communication of intention to grant the patent
06.03.2019Fee for grant paid
06.03.2019Fee for publishing/printing paid
06.03.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP04781429.8  / EP1663182
EP10014567.1  / EP2316442
EP14163366.9  / EP2821067
EP17185704.8  / EP3260117
Opposition(s)Opponent(s)01  13.01.2020  04.08.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  16.01.2020  22.01.2020  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
 03  16.01.2020  22.01.2020  ADMISSIBLE
Gillard, Richard Edward
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 04  16.01.2020  22.01.2020  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2, 1st Floor
Croxley Green Business Park
Watford
Hertfordshire WD18 8YA / GB
Opponent's representative
Schlich, George William
Schlich
9 St. Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
 05  17.01.2020  22.01.2020  ADMISSIBLE
BIOGARAN
15 Boulevard Charles de Gaulle
92707 COLOMBES / FR
Opponent's representative
Casalonga
31 Rue de Fleurus
75006 Paris / FR
 06  17.01.2020  22.01.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Ellis, Robin Patrick
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
 07  17.01.2020  22.01.2020  ADMISSIBLE
Maiwald GmbH
Elisenhof
Elisenstr. 3
80335 München / DE
 08  17.01.2020  22.01.2020  ADMISSIBLE
Aechter, Bernd
Nymphenburgerstrasse 4
80335 München / DE
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 09  17.01.2020  02.07.2021  WITHDRAWN
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 10  09.12.2020  11.12.2020  INTERVENTION ADMISSIBLE
betapharm Arzneimittel GmbH
Kobelweg 95
86156 Augsburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 11  23.12.2020  11.01.2021  INTERVENTION ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Vos, Derk
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 [N/P]
Former [2022/15]
Opponent(s)01  13.01.2020  04.08.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  16.01.2020  22.01.2020  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
 03  16.01.2020  22.01.2020  ADMISSIBLE
Gillard, Richard Edward
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 04  16.01.2020  22.01.2020  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2, 1st Floor
Croxley Green Business Park
Watford
Hertfordshire WD18 8YA / GB
Opponent's representative
Schlich, George
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
 05  17.01.2020  22.01.2020  ADMISSIBLE
BIOGARAN
15 Boulevard Charles de Gaulle
92707 COLOMBES / FR
Opponent's representative
Casalonga
31 Rue de Fleurus
75006 Paris / FR
 06  17.01.2020  22.01.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Ellis, Robin Patrick
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
 07  17.01.2020  22.01.2020  ADMISSIBLE
MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH
Elisenhof
Elisenstr. 3
80335 München / DE
 08  17.01.2020  22.01.2020  ADMISSIBLE
Aechter, Bernd
Nymphenburgerstrasse 4
80335 München / DE
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 09  17.01.2020  02.07.2021  WITHDRAWN
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 10  09.12.2020  11.12.2020  INTERVENTION ADMISSIBLE
betapharm Arzneimittel GmbH
Kobelweg 95
86156 Augsburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 11  23.12.2020  11.01.2021  INTERVENTION ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Vos, Derk
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2022/11]
Opponent(s)01  13.01.2020  04.08.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  16.01.2020  22.01.2020  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
 03  16.01.2020  22.01.2020  ADMISSIBLE
Gillard, Richard Edward
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 04  16.01.2020  22.01.2020  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2, 1st Floor
Croxley Green Business Park
Watford
Hertfordshire WD18 8YA / GB
Opponent's representative
Schlich, George
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
 05  17.01.2020  22.01.2020  ADMISSIBLE
BIOGARAN
15 Boulevard Charles de Gaulle
92707 COLOMBES / FR
Opponent's representative
Casalonga
31 Rue de Fleurus
75006 Paris / FR
 06  17.01.2020  22.01.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Ellis, Robin Patrick
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
 07  17.01.2020  22.01.2020  ADMISSIBLE
MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH
Elisenhof
Elisenstr. 3
80335 München / DE
 08  17.01.2020  22.01.2020  ADMISSIBLE
Aechter, Bernd
Nymphenburgerstrasse 4
80335 München / DE
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 09  17.01.2020  02.07.2021  WITHDRAWN
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 10  09.12.2020  11.12.2020  ADMISSIBLE
betapharm Arzneimittel GmbH
Kobelweg 95
86156 Augsburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 11  23.12.2020  11.01.2021  INTERVENTION ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Vos, Derk
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2021/36]
Opponent(s)01  13.01.2020  04.08.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  16.01.2020  22.01.2020  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
 03  16.01.2020  22.01.2020  ADMISSIBLE
Gillard, Richard Edward
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 04  16.01.2020  22.01.2020  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2, 1st Floor
Croxley Green Business Park
Watford
Hertfordshire WD18 8YA / GB
Opponent's representative
Schlich, George
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
 05  17.01.2020  22.01.2020  ADMISSIBLE
BIOGARAN
15 Boulevard Charles de Gaulle
92707 COLOMBES / FR
Opponent's representative
Casalonga
31 Rue de Fleurus
75006 Paris / FR
 06  17.01.2020  22.01.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Ellis, Robin Patrick
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
 07  17.01.2020  22.01.2020  ADMISSIBLE
MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH
Elisenhof
Elisenstr. 3
80335 München / DE
 08  17.01.2020  22.01.2020  ADMISSIBLE
Aechter, Bernd
Nymphenburgerstrasse 4
80335 München / DE
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 09  17.01.2020  02.07.2021  WITHDRAWN
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 10  09.12.2020  11.12.2020  ADMISSIBLE
betapharm Arzneimittel GmbH
Kobelweg 95
86156 Augsburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 11  23.12.2020  11.01.2021  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Vos, Derk
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2021/32]
Opponent(s)01  13.01.2020  15.01.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  16.01.2020  22.01.2020  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
 03  16.01.2020  22.01.2020  ADMISSIBLE
Gillard, Richard Edward
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 04  16.01.2020  22.01.2020  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2, 1st Floor
Croxley Green Business Park
Watford
Hertfordshire WD18 8YA / GB
Opponent's representative
Schlich, George
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
 05  17.01.2020  22.01.2020  ADMISSIBLE
BIOGARAN
15 Boulevard Charles de Gaulle
92707 COLOMBES / FR
Opponent's representative
Casalonga
31 Rue de Fleurus
75006 Paris / FR
 06  17.01.2020  22.01.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Ellis, Robin Patrick
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
 07  17.01.2020  22.01.2020  ADMISSIBLE
MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH
Elisenhof
Elisenstr. 3
80335 München / DE
 08  17.01.2020  22.01.2020  ADMISSIBLE
Aechter, Bernd
Nymphenburgerstrasse 4
80335 München / DE
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 09  17.01.2020  02.07.2021  WITHDRAWN
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 10  09.12.2020  11.12.2020  ADMISSIBLE
betapharm Arzneimittel GmbH
Kobelweg 95
86156 Augsburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 11  23.12.2020  11.01.2021  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Vos, Derk
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2021/20]
Opponent(s)01  13.01.2020  15.01.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  16.01.2020  22.01.2020  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
 03  16.01.2020  22.01.2020  ADMISSIBLE
Gillard, Richard Edward
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 04  16.01.2020  22.01.2020  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2, 1st Floor
Croxley Green Business Park
Watford
Hertfordshire WD18 8YA / GB
Opponent's representative
Schlich, George
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
 05  17.01.2020  22.01.2020  ADMISSIBLE
BIOGARAN
15 Boulevard Charles de Gaulle
92707 COLOMBES / FR
Opponent's representative
Casalonga
31 Rue de Fleurus
75006 Paris / FR
 06  17.01.2020  22.01.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Ellis, Robin Patrick
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
 07  17.01.2020  22.01.2020  ADMISSIBLE
MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH
Elisenhof
Elisenstr. 3
80335 München / DE
 08  17.01.2020  22.01.2020  ADMISSIBLE
Aechter, Bernd
Nymphenburgerstrasse 4
80335 München / DE
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 09  17.01.2020  22.01.2020  ADMISSIBLE
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 10  09.12.2020  11.12.2020  ADMISSIBLE
betapharm Arzneimittel GmbH
Kobelweg 95
86156 Augsburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 11  23.12.2020  11.01.2021  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Vos, Derk
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2021/07]
Opponent(s)01  13.01.2020  15.01.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  16.01.2020  22.01.2020  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
 03  16.01.2020  22.01.2020  ADMISSIBLE
Gillard, Richard Edward
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 04  16.01.2020  22.01.2020  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2, 1st Floor
Croxley Green Business Park
Watford
Hertfordshire WD18 8YA / GB
Opponent's representative
Schlich, George
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
 05  17.01.2020  22.01.2020  ADMISSIBLE
BIOGARAN
15 Boulevard Charles de Gaulle
92707 COLOMBES / FR
Opponent's representative
Casalonga
31 Rue de Fleurus
75006 Paris / FR
 06  17.01.2020  22.01.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Ellis, Robin Patrick
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
 07  17.01.2020  22.01.2020  ADMISSIBLE
MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH
Elisenhof
Elisenstr. 3
80335 München / DE
 08  17.01.2020  22.01.2020  ADMISSIBLE
Aechter, Bernd
Nymphenburgerstrasse 4
80335 München / DE
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 09  17.01.2020  22.01.2020  ADMISSIBLE
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 10  09.12.2020  11.12.2020  ADMISSIBLE
betapharm Arzneimittel GmbH
Kobelweg 95
86156 Augsburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 11  23.12.2020  11.01.2021  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Vos, Derk
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2021/03]
Opponent(s)01  13.01.2020  15.01.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  16.01.2020  22.01.2020  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
 03  16.01.2020  22.01.2020  ADMISSIBLE
Gillard, Richard Edward
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 04  16.01.2020  22.01.2020  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2, 1st Floor
Croxley Green Business Park
Watford
Hertfordshire WD18 8YA / GB
Opponent's representative
Schlich, George
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
 05  17.01.2020  22.01.2020  ADMISSIBLE
BIOGARAN
15 Boulevard Charles de Gaulle
92707 COLOMBES / FR
Opponent's representative
Casalonga
31 Rue de Fleurus
75006 Paris / FR
 06  17.01.2020  22.01.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Ellis, Robin Patrick
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
 07  17.01.2020  22.01.2020  ADMISSIBLE
MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH
Elisenhof
Elisenstr. 3
80335 München / DE
 08  17.01.2020  22.01.2020  ADMISSIBLE
Aechter, Bernd
Nymphenburgerstrasse 4
80335 München / DE
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 09  17.01.2020  22.01.2020  ADMISSIBLE
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 10  09.12.2020  11.12.2020  ADMISSIBLE
betapharm Arzneimittel GmbH
Kobelweg 95
86156 Augsburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
Former [2020/30]
Opponent(s)01  13.01.2020  15.01.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  16.01.2020  22.01.2020  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
 03  16.01.2020  22.01.2020  ADMISSIBLE
Gillard, Richard Edward
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 04  16.01.2020  22.01.2020  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2, 1st Floor
Croxley Green Business Park
Watford
Hertfordshire WD18 8YA / GB
Opponent's representative
Schlich, George
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
 05  17.01.2020  22.01.2020  ADMISSIBLE
BIOGARAN
15 Boulevard Charles de Gaulle
92707 COLOMBES / FR
Opponent's representative
Casalonga
31 Rue de Fleurus
75006 Paris / FR
 06  17.01.2020  22.01.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Ellis, Robin Patrick
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
 07  17.01.2020  22.01.2020  ADMISSIBLE
MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH
Elisenhof
Elisenstr. 3
80335 München / DE
 08  17.01.2020  22.01.2020  ADMISSIBLE
Aechter, Bernd
Nymphenburgerstrasse 4
80335 München / DE
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 09  17.01.2020  22.01.2020  ADMISSIBLE
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
Former [2020/09]
Opponent(s)01  13.01.2020  15.01.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  16.01.2020  22.01.2020  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
 03  16.01.2020  22.01.2020  ADMISSIBLE
Gillard, Richard Edward
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 04  16.01.2020  22.01.2020  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2, 1st Floor
Croxley Green Business Park
Watford
Hertfordshire WD18 8YA / GB
Opponent's representative
Schlich, George
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
 05  17.01.2020  22.01.2020  ADMISSIBLE
BIOGARAN
15 Boulevard Charles de Gaulle
92707 COLOMBES / FR
Opponent's representative
Casalonga
31 Rue de Fleurus
75006 Paris / FR
 06  17.01.2020  22.01.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Ellis, Robin Patrick
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
 07  17.01.2020  22.01.2020  ADMISSIBLE
MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH
Elisenhof
Elisenstr. 3
80335 München / DE
 08  17.01.2020  22.01.2020  ADMISSIBLE
Aechter, Bernd
Nymphenburgerstrasse 4
80335 München / DE
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 09  17.01.2020  22.01.2020  ADMISSIBLE
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
Former [2020/08]
Opponent(s)01  13.01.2020  15.01.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  16.01.2020   
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
05.02.2020Invitation to proprietor to file observations on the notice of opposition
17.08.2020Reply of patent proprietor to notice(s) of opposition
13.07.2021Date of oral proceedings
16.12.2021Despatch of minutes of oral proceedings
16.12.2021Despatch of communication that the patent will be revoked
10.10.2022Legal effect of revocation of patent [2022/46]
Appeal following opposition28.02.2022Appeal received No.  T0591/22
28.02.2022Payment of appeal fee
23.09.2022Result of appeal procedure: appeal of the proprietor inadmissible
30.09.2022Despatch of the decision of the Board of Appeal
Fees paidRenewal fee
01.06.2018Renewal fee patent year 03
01.06.2018Renewal fee patent year 04
01.06.2018Renewal fee patent year 05
01.06.2018Renewal fee patent year 06
01.06.2018Renewal fee patent year 07
01.06.2018Renewal fee patent year 08
01.06.2018Renewal fee patent year 09
01.06.2018Renewal fee patent year 10
01.06.2018Renewal fee patent year 11
01.06.2018Renewal fee patent year 12
01.06.2018Renewal fee patent year 13
01.06.2018Renewal fee patent year 14
11.09.2018Renewal fee patent year 15
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[YD]US6211244  (VAN WAGENEN BRADFORD C [US], et al) [YD] 1-15 * abstract * * table 3 * * column 1, line 65 - column 6, line 67 *;
 [Y]US6313146  (VAN WAGENEN BRADFORD C [US], et al) [Y] 1-15 * the whole document *;
 [Y]  - ANONYMOUS, "Amgen submitted new drug application for Cinacalcet HCI", (20030908), AMGEN NEWS RELEASE, URL: http://www.amgen.com/news/news03/pressRelease030908a.pdf, (20050112), XP002313388 [Y] 1-15 * the whole document *
 [Y]  - GOODMAN WILLIAM G ET AL, "The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN. APR 2002, (200204), vol. 13, no. 4, ISSN 1046-6673, pages 1017 - 1024, XP002313387 [Y] 1-15 * the whole document *
 [A]  - ANONYMOUS, "NPS-Drug Development: Product Develpment Pipeline", (20030908), INTERNET ARTICLE, URL: www.npsp.com/drug_development/pipeline.php, (20050112), XP002313391 [A] 1-15 * the whole document *
by applicantWO9304373
 WO9418959
 WO9511221
 WO9612697
 WO9741090
 EP0933354
 US5981599
 US6001884
 US6011068
 US6031003
 US6172091
 US6211244
 WO0134562
 US6313146
 US6342532
 US6363231
 US2002107406
 US6432656
    - BERGE et al., J. Pharm. Sci., (19770000), vol. 66, page 1
OppositionUS6211244
 US6313146
 WO2005034928
 EP1663182
 EP1663182
 US9375405
 WO03086343
 EP2316442
 EP2821067
 EP2821067
 EP3260117
 EP3395339
 EP3260117
 EP3395340
 EP3395338
 EP3578175
 US6596311
 EP1663182
    - FRANCESCHINI N; JOY M S; KSHIRSAGAR A, "Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opin Investig Drugs, (20030812), vol. 12, no. 8, pages 1413 - 1421, XP009083254

DOI:   http://dx.doi.org/10.1517/13543784.12.8.1413
    - Raymond C Rowe Et Al.,, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, Sixth Edition, Pharmaceutical Press, (20090000), pages 2pp, 129-131,185,186,208,404,581,582,691 - 692, XP055671872
    - GIBALDI, GIBALDI, Milo Gibaldi, Biopharmaceutics and Clinical Pharmacokinetics, fourth edition,, Lea& Febiger, (19910000), vol. 2pp, 51, XP055282823
    - Deodatt A Wadke, "Chapter 1 - Preformulation Testing", Deodatt A Wadke, LIEBERMAN et al., Pharmaceutical Dosage Forms: Tablets, Volume 1, 2nd ed,, (19890000), pages 1 - 24, XP055416092
    - Eugene F. Fiese, Timothy A. Hagen, "Preformulation", Eugene F. Fiese, Timothy A. Hagen, Leon Lachman, Herbert A Lieberman and Joseph L Kanig, The Theory and Practice of Industrial Pharmacy, Third Edition, Lea & Febiger, (19870000), pages 171-197, 298 - 303, XP055671875
    - "Super Disintegrants: Characterization and Function", Swarbrick J; Et Al, Encyclopaedia of Pharmaceutical Technology. Vol 20,, Marcel Dekker, (2001), pages 269 - 293, XP055512903

DOI:   http://dx.doi.org/10.1201/b19309-12
    - GISSINGER D; STAMM A, "A Comparative Evaluation of the Properties of some Tablet Disintegrants", Drug Development and Industrial Pharmacy, (19800000), vol. 6, no. 5, pages 511 - 536, XP008063508

DOI:   http://dx.doi.org/10.3109/03639048009068720
    - Ainley Wade, Paul J. Weller, Handbook of Pharmaceutical Excipients, Second Edition, American Pharmaceutical Association, (19940000), pages 483 - 493, XP055671886
    - Michael E. Aulton, Pharmaceutics: The Science of Dosage Form Design, Second Edition, Spain, Elsevier, (20020000), pages 113-138, 397 - 440, XP055671888
    - L. D. Quarles, et al.,, "The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease", Journal of the American Society of Nephrology, (20030000), vol. 14, pages 575 - 583, XP055671891

DOI:   http://dx.doi.org/10.1097/01.ASN.0000050224.03126.AD
    - Anonymous, "Chemistry Review(s)", Center for Drug Evaluation and Research Application Number: 21-688, (2004), page 22pp, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Chemr.pdf, XP055671894
    - Anonymous, "A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis", ClinicalTrials.gov /NCT00042653/, (20020806), URL: https://clinicaltrials.gov/ct2/show/NCT00042653, XP055671896
    - Anonymous, "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations", U.S. Food and Drug Administration /FDA/, URL: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=021688&Appl_type=N
    - ANONYMOUS, "Amgen submitted new drug application for Cinacalcet HCI", AMGEN NEWS RELEASE, (20030908), URL: http://www.amgen.com/news/n ews03/pressRelease030908a. pdf, (20050112), XP002313388
    - GOODMAN WILLIAM G et al., "The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY: JASN. APR 2002, (20020400), vol. 13, no. 4, ISSN 1 046-6673, pages 1017 - 1024, XP002313387
    - FRANCE SCHINI et al., "Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opin Investig Drugs, (20030000), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, pages 1413 - 21, XP009083254

DOI:   http://dx.doi.org/10.1517/13543784.12.8.1413
    - QUARLES, L.D. et al., "The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease", Am Soc Nephrol, (20030300), vol. 14, pages 575 - 583, XP055671891

DOI:   http://dx.doi.org/10.1097/01.ASN.0000050224.03126.AD
    - Anonymus, "Chapter 18: Tablets", Pharmaceutics: The Science of Dosage Form Design, (19880000), pages 304 - 305, XP055673010
    - Anonymus, Pharmaceutics: The Science of Dosage Form Design, (20020000), pages 404 - 408, XP055673015
    - L. LACHMAN et al., The theory and Practice of Industrial Pharmacy, (19860000), pages 324 - 328, XP055673018
    - AULTON M.E, Pharmaceutics: The Science of Dosage Form Design, New York, (19880000), pages 311 - 312, XP055673027
    - Remington - The Science and Practice of Pharmacy, (20000000), vol. 1, page 862, XP055673031
    - Anonymus, "Clinical Pharmacology and Biopharmaceutics Review. Application Number 21-688", Center for Drug Evaluation and Research, (20030905), pages 1 - 53, XP055673474
    - Rudolf Voigt, "Tabletten", PHARMAZEUTISCHE TECHNOLOGIE : FÜR STUDIUM UND BERUF, Stuttgart, Deutscher Apotheker Verlag, (20000101), pages 163 - 187, XP055673408
    - U. V. Banakar, "Factors That Influence Dissolution Testing", Pharmaceutical Dissolution Testing, (19920101), pages 136 - 145, ISBN 978-0-8247-8567-3, XP055308585
    - Leon Lachman, Et Al, "The Theory and Practice of Industrial Pharmacy, third edition", The Theory and Practice of Industrial Pharmacy, third edition, Lea & Febiger, (19860101), pages 189, 321 - 324-329, XP055673418
    - FRANCESCHINI N. et al, "CINACALCET HCI: A CALCIMIMETIC AGENT FOR THE MANAGEMENT OF PRIMARY AND SECONDARY HYPERPARATHYROIDISM", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK, (20030101), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, ISSN 1354-3784, pages 1413 - 1421, XP009083254

DOI:   http://dx.doi.org/10.1517/13543784.12.8.1413
    - Alfonso R. Gennaro, "Oral Solid Dosage Forms", REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, (20000101), vol. 704, pages 858 - 893, XP055673423
    - Raymond C. Rowe et al, "Cellulose, Microcrystalline / Starch", HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, PHARMACEUTICAL PRESS, (20030529), pages 108 - 603-611, XP055673426
    - Kathleen M. Lee, "Unit 7.3: Overview of Drug Product Development", Current Protocols in Pharmacology, (20010101), pages 7.3.1 - 7.3.10, XP055319345
    - Joseph P. Remington, "Dissolution", Joseph P. Remington, Gennaro Alfonso R., Remington: the science and practice of pharmacy, Easton, Pennsylvania, Mack Publishing Company, (19950101), page 2pp, 595, ISBN 978-0-912734-04-0, XP055282825
    - RITSCHEL et al., "Die Tablette", (20020000), pages 332 - 335, XP55673487
    - Lieberman Herbert A. et al, Pharmaceutical Dosage Forms, Chapters 3 and 4, New York, Basel, Hong Kong, Marcel Dekker Inc., (19900000), vol. 1
    - Anonymous, "Chemistry Review(s)", Center for Drug Evaluation and Research Application Number: 21-688, page 22pp, Center for Drug Evaluation and Research Application Number: 21-688, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Chemr.pdf, (20200226), XP055671894
    - Anonymous, "A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis", ClinicalTrials.gov /NCT00042653/, ClinicalTrials.gov /NCT00042653/, URL: https://clinicaltrials.gov/ct2/show/NCT00042653, (20200226), XP055671896
    - Anonymous, "Clinical Pharmacology and Biopharmaceutics Review. Application Number 21-688", Center for Drug Evaluation and Research, (20030905), pages 1 - 53, XP055673474
    - Fda, "Drug approval Package: Sensipar (Cinacalcet HCI) NDA #021688", URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688_Sensipar.cfm, (20200304), XP055673613
    - A. Wade et al, "Microcrystalline Cellulose / Crospovidone / Pregelatinized Starch", Handbook of pharmaceutical excipients, 2nd ed, (19940101), pages 84-87 - 143-144 491- 493, XP055673621
    - Eugene F. Fiese, Timothy A. Hagen, "Preformulation", The Theory and Practice of Industrial Pharmacy, Third Edition, Lea & Febiger, (19870101), pages 171-197 - 298-303, XP055671875
    - Milo Gibaldi, "Biopharmaceutics and Clinical Pharmacokinetics, fourth edition", Biopharmaceutics and Clinical Pharmacokinetics, fourth edition, Lea& Febiger, (19910101), page 2pp, 51, ISBN 978-0-8121-1346-4, XP055282823
    - Swarbrick J. et al, "Super Disintegrants: Characterization and Function", Encyclopaedia of Pharmaceutical Technology, Marcel Dekker, (20010101), vol. 20, pages 269 - 293, XP055512903

DOI:   http://dx.doi.org/10.1201/b19309-12
    - Eugene F. Fiese et al, "Preformulation", The Theory and Practice of Industrial Pharmacy, Third Edition, Lea & Febiger, (19870101), pages 171 - 303, XP055671875
    - FRANCE SCHINI, N et al., "Cinacalcet HC1 : a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert opin. Investig. Drugs, (20030000), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, pages 1413 - 1421, XP009083254

DOI:   http://dx.doi.org/10.1517/13543784.12.8.1413
    - Gennaro et al., "Chapter 45 - Oral Solid Dosage Forms", Remington: The Science and Practice of Pharmacy, (2000), pages 858 - 893, XP055301374
    - Kathleen M Lee, "Unit 7.3: Overview of Drug Product Development", Current Protocols in Pharmacology, (20010000), pages 7.3.1 - 7.3.10, XP055319345
    - AULTON, "Dosage form design and manufacture", Pharmaceutics: The Science of Dosage Form Design, (20020000), pages 404 - 408, XP055673015
    - GOODMAN WILLIAM G et al., "The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism", Journal of the American Society of Nephrology, vol. 13, no. 4, pages 1017 - 1024, XP002387352
    - "Amgen Submitted New Drug Application for Cinacalcet HC1", Amgen News Release, (20030908), XP055674150
    - A. LE HIR, "Abrégé de pharmacie galénique formes pharmaceutiques", Abrégé de pharmacie galénique formes pharmaceutiques,, (19810000), pages 94-95,104 - 105,204-209,205-255, XP055673484
    - "1 Preformulation Testing", LIEBERMAN et al., Pharmaceutical Dosage Forms: Tablets volume 1, (19890000), pages 1 - 73, XP009184711
    - MICHAEL AULTON, "Factors influencing bioavailability: factors influencing drug absorption from the gastrointestinal tract", PHARMACEUTICS :THE SCIENCE OF DOSAGE FORM DESIGN,, (19880000), pages 135,156 - 157, XP055673473
    - GIBALDI, "Gastrointestinal Absorption - Physicochemical Considerations", Biopharmaceutics and Clinical Pharmacokinetics, fourth edition, (19910000), page 51, XP055282823
    - J.C CHAUMEIL, "Micronisation : a method for improving the bioavailability of poorly soluble drugs", Meth Find Clin. Pharmacol, (19980000), pages 211 - 215, XP055673475
    - FRANCESCHINI N; ET AL, "Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opinion on Investigational Drugs, (20030000), doi:10.1517/13543784.12.8.1413, pages 1413 - 1421, XP009083254

DOI:   http://dx.doi.org/10.1517/13543784.12.8.1413
    - KLANCKE J, "Dissolution Testing of Orally Disintegrating Tablets", DISSOLUTION TECHNOLOGIES, (20030000), pages 6 - 8, XP002545423
    - FRANCESCHINI N. et al, "CINACALCET HCI: A CALCIMIMETIC AGENT FOR THE MANAGEMENT OF PRIMARY AND SECONDARY HYPERPARATHYROIDISM", Expert Opinion on Investigational Drugs, UK, (20030101), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, ISSN 1354-3784, pages 1413 - 1421, XP009083254

DOI:   http://dx.doi.org/10.1517/13543784.12.8.1413
    - Alfonso R. Gennaro, "Oral Solid Dosage Forms", REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, (20000101), pages 704 - 858-893, XP055673423
    - Raymond C. Rowe et al, "Cellulose, Microcrystalline / Starch", HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, PHARMACEUTICAL PRESS, (20030529), pages 108-111 - 603-611, XP055673426
    - Wolfgang A. Ritschel, Die Tablette, Handbuch der Entwicklung, Herstellung und Qualitätssicherung, 2. Auflage, Editio Cantor Verlag Aulendorf, (20020000), pages 332 - 335, XP055673487
    - LIEBERMAN HERBERT A. ET AL: "Pharmaceutical Dosage Forms, Chapters 3 and 4", vol. 1, 1990, MARCEL DEKKER INC., New York, Basel, Hong Kong
    - CHAPTER16, CHAPTER16, Hans Leuenberger,, Martin . Fhysikafedte Pharmasie, (2002), pages 656 - 662, XP055784935
    - "crospovidone", Raymon C Rowe et al, Handbook of pharmaceutical excipients, (2006), XP055784959
    - "CHAPTER4", RITSCHEL W A, RITSCHEL W A Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung,, (2002), pages 268 - 277, XP055274661
    - "15.7 Polyvinylpyrrolidon, quervernetzt", P. C. Schmidt, Tubingen et al, Wirk- und Hilffsstofffe fiir Rezeptur, Defektur und GroBherstellunq, (1999), page 267, XP055784967
    - "Compressed Tablets by Wet Granulation", LibermanH ET AL, Pharmaceutical Dosage Forms, (1989), pages 92,149 - 150, XP055784979
    - "Lactose-MonohydratLactosum monohydricum", Kommentar zur Ph. Eur. 9.0, (2017), pages 1 - 5, XP055784984
    - Karande, A.D. ; Heng, P.W.S. ; Liew, C.V., "In-line quantification of micronized drug and excipients in tablets by near infrared (NIR) spectroscopy: Real time monitoring of tabletting process", INTERNATIONAL JOURNAL OF PHARMACEUTICS, (20100830), vol. 396, pages 63 - 74, XP027169573
    - "Magnesiumstearat", Magnesiumstearat
    - Raymond C Rowe et al, "Croscarmellose sodium", Handbook of Pharmaceutical Excipients, (2006), pages 211-216 ,702 - 704, XP055784136
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.